Cargando…
Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498956/ https://www.ncbi.nlm.nih.gov/pubmed/36137153 http://dx.doi.org/10.1371/journal.pone.0274089 |
_version_ | 1784794889400090624 |
---|---|
author | Shetty, Omshree Shet, Tanuja Iyer, Ramya Gogte, Prachi Gurav, Mamta Joshi, Pradnya Karnik, Nupur Pai, Trupti Epari, Sridhar Desai, Sangeeta |
author_facet | Shetty, Omshree Shet, Tanuja Iyer, Ramya Gogte, Prachi Gurav, Mamta Joshi, Pradnya Karnik, Nupur Pai, Trupti Epari, Sridhar Desai, Sangeeta |
author_sort | Shetty, Omshree |
collection | PubMed |
description | BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for improving quality. Outbreak of COVID-19 pandemic led to worldwide lockdown and disruption of healthcare services including participation in EQAS.The present study describes the extended scope of EQAS offered byMPQAP (Molecular Pathology Quality Assurance Program), the first proficiency test provider for solid tumor diagnostics in India. The study surveys the preparedness of molecular testing laboratories in routine diagnostics and participation for quality assessment scheme. METHODS: A documented guideline for measures and precautions to be carried by testing laboratories in performing routine diagnostic tests during the lockdown period were charted and distributed to all MPQAP participant centres. A survey was conducted for MPQAP participants to check whether laboratories were involved in COVID-19 testing and to evaluate the impact of lockdown on the operations of diagnostics procedures. From the acquired response of the survey, 2 cycles out of initially proposed 11 cycles were executed with transformed approach using digital tools and image interpretation modules. FINDINGS: Out of 25 solid tumour testing laboratories registered as participants, 15 consented to participate in survey. The summary of survey conveyed the impact of COVID-19onroutine operations of diagnostics tests such as shortcomings in inventory and human resource management. Thirteen participants showed active willingness and consented to participate in EQAS test scheme. INTERPRETATIONS: The survey findings and assessment of EQAS cycles endorsed the quality testing procedures carried by participating laboratories throughout the lockdown. It highlighted the utility of EQAS participation during pandemic along with emphasis on safety measures for continual improvement in quality of diagnostic services. |
format | Online Article Text |
id | pubmed-9498956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94989562022-09-23 Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India Shetty, Omshree Shet, Tanuja Iyer, Ramya Gogte, Prachi Gurav, Mamta Joshi, Pradnya Karnik, Nupur Pai, Trupti Epari, Sridhar Desai, Sangeeta PLoS One Research Article BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for improving quality. Outbreak of COVID-19 pandemic led to worldwide lockdown and disruption of healthcare services including participation in EQAS.The present study describes the extended scope of EQAS offered byMPQAP (Molecular Pathology Quality Assurance Program), the first proficiency test provider for solid tumor diagnostics in India. The study surveys the preparedness of molecular testing laboratories in routine diagnostics and participation for quality assessment scheme. METHODS: A documented guideline for measures and precautions to be carried by testing laboratories in performing routine diagnostic tests during the lockdown period were charted and distributed to all MPQAP participant centres. A survey was conducted for MPQAP participants to check whether laboratories were involved in COVID-19 testing and to evaluate the impact of lockdown on the operations of diagnostics procedures. From the acquired response of the survey, 2 cycles out of initially proposed 11 cycles were executed with transformed approach using digital tools and image interpretation modules. FINDINGS: Out of 25 solid tumour testing laboratories registered as participants, 15 consented to participate in survey. The summary of survey conveyed the impact of COVID-19onroutine operations of diagnostics tests such as shortcomings in inventory and human resource management. Thirteen participants showed active willingness and consented to participate in EQAS test scheme. INTERPRETATIONS: The survey findings and assessment of EQAS cycles endorsed the quality testing procedures carried by participating laboratories throughout the lockdown. It highlighted the utility of EQAS participation during pandemic along with emphasis on safety measures for continual improvement in quality of diagnostic services. Public Library of Science 2022-09-22 /pmc/articles/PMC9498956/ /pubmed/36137153 http://dx.doi.org/10.1371/journal.pone.0274089 Text en © 2022 Shetty et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Shetty, Omshree Shet, Tanuja Iyer, Ramya Gogte, Prachi Gurav, Mamta Joshi, Pradnya Karnik, Nupur Pai, Trupti Epari, Sridhar Desai, Sangeeta Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title | Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title_full | Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title_fullStr | Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title_full_unstemmed | Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title_short | Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India |
title_sort | impact of covid-19 on quality checks of solid tumor molecular diagnostic testing-a surveillance by eqas provider in india |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498956/ https://www.ncbi.nlm.nih.gov/pubmed/36137153 http://dx.doi.org/10.1371/journal.pone.0274089 |
work_keys_str_mv | AT shettyomshree impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT shettanuja impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT iyerramya impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT gogteprachi impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT guravmamta impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT joshipradnya impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT karniknupur impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT paitrupti impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT eparisridhar impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia AT desaisangeeta impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia |